Analysts Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $67.70

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have been assigned a consensus recommendation of “Buy” from the twelve research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold recommendation, ten have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $67.70.

A number of research firms recently commented on JANX. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price target on shares of Janux Therapeutics in a research note on Thursday, November 7th. UBS Group assumed coverage on shares of Janux Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $69.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $100.00 price target on shares of Janux Therapeutics in a report on Thursday, November 7th. Leerink Partnrs raised shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, November 22nd. Finally, Leerink Partners started coverage on Janux Therapeutics in a research note on Friday, November 22nd. They set an “outperform” rating and a $79.00 target price for the company.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, Director Ra Capital Management, L.P. purchased 1,200,000 shares of the firm’s stock in a transaction on Friday, October 18th. The stock was purchased at an average cost of $44.75 per share, for a total transaction of $53,700,000.00. Following the transaction, the director now owns 9,317,246 shares in the company, valued at $416,946,758.50. The trade was a 14.78 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Ventures Xi L.P. Avalon sold 958 shares of Janux Therapeutics stock in a transaction on Monday, September 30th. The stock was sold at an average price of $46.24, for a total transaction of $44,297.92. Following the transaction, the insider now owns 6,887 shares in the company, valued at approximately $318,454.88. This trade represents a 12.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 445,610 shares of company stock valued at $20,578,666 in the last 90 days. 29.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Janux Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC lifted its stake in shares of Janux Therapeutics by 40.0% in the third quarter. Janus Henderson Group PLC now owns 2,523,406 shares of the company’s stock worth $114,587,000 after acquiring an additional 721,563 shares during the period. Logos Global Management LP lifted its position in shares of Janux Therapeutics by 400.0% in the 2nd quarter. Logos Global Management LP now owns 750,000 shares of the company’s stock worth $31,418,000 after purchasing an additional 600,000 shares during the period. Vanguard Group Inc. lifted its position in shares of Janux Therapeutics by 38.6% in the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock worth $51,127,000 after purchasing an additional 378,477 shares during the period. Point72 Asset Management L.P. boosted its stake in shares of Janux Therapeutics by 190.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 395,875 shares of the company’s stock valued at $17,985,000 after purchasing an additional 259,445 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Janux Therapeutics by 202.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock worth $10,639,000 after buying an additional 156,675 shares during the period. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Stock Down 3.4 %

Shares of NASDAQ:JANX opened at $46.39 on Tuesday. Janux Therapeutics has a 12-month low of $7.79 and a 12-month high of $65.60. The company’s 50 day moving average price is $49.98 and its two-hundred day moving average price is $45.83. The firm has a market cap of $2.43 billion, a PE ratio of -39.65 and a beta of 3.52.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The company had revenue of $0.44 million for the quarter, compared to analyst estimates of $1.50 million. Janux Therapeutics’s quarterly revenue was down 82.6% compared to the same quarter last year. On average, research analysts expect that Janux Therapeutics will post -1.35 EPS for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.